Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 5 (2008), Issue 1 (January)

1. Decreased expression of human D-glucuronyl C5-epimerase in breast cancer.
   Int J Cancer, 122(5): 1172-6. [Abstract] [Full-text]
2. HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy.
   Int J Cancer, 122(5): 999-1004. [Abstract] [Full-text]
3. Family history of breast or ovarian cancer modifies the risk of secondary leukemia after breast cancer: results from a population-based study.
   Int J Cancer, 122(5): 1114-7. [Abstract] [Full-text]
4. Interactions between intakes of alcohol and postmenopausal hormones on risk of breast cancer.
   Int J Cancer, 122(5): 1109-13. [Abstract] [Full-text]
5. Prognostic effect of estrogen receptor status across age in primary breast cancer.
   Int J Cancer, 122(5): 1089-94. [Abstract] [Full-text]
6. Production of P-glycoprotein from the MDR1 upstream promoter is insufficient to affect the response to first-line chemotherapy in advanced breast cancer.
   Int J Cancer, 122(5): 1058-67. [Abstract] [Full-text]
7. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
   J Natl Cancer Inst, 100(1): 14-20. [Abstract] [Full-text]
8. High-resolution mapping of DNA breakpoints to define true recurrences among ipsilateral breast cancers.
   J Natl Cancer Inst, 100(1): 48-58. [Abstract] [Full-text]
9. Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study.
   J Natl Cancer Inst, 100(1): 32-40. [Abstract] [Full-text]
10. Phosphorylation of focal adhesion kinase promotes extravasation of breast cancer cells.
    Biochem Biophys Res Commun, 366(2): 476-82. [Abstract] [Full-text]
11. Care in the months before death and hospice enrollment among older women with advanced breast cancer.
    J Gen Intern Med, 23(1): 11-8. [Abstract] [Full-text]
12. Proliferation-associated Brn-3b transcription factor can activate cyclin D1 expression in neuroblastoma and breast cancer cells.
    Oncogene, 27(1): 145-54. [Abstract] [Full-text]
13. Wilms' tumor protein 1: an early target of progestin regulation in T-47D breast cancer cells that modulates proliferation and differentiation.
    Oncogene, 27(1): 126-38. [Abstract] [Full-text]
14. Risky business: medical discourse, breast cancer, and narrative.
    Qual Health Res, 18(1): 65-76. [Abstract] [Full-text]
15. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials.
    Lancet, 371(9606): 29-40. [Abstract] [Full-text]
16. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.
    Lancet Oncol, 9(1): 45-53. [Abstract] [Full-text]
17. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
    Lancet Oncol, 9(1): 23-8. [Abstract] [Full-text]
18. Double-stranded RNA-binding protein regulates vascular endothelial growth factor mRNA stability, translation, and breast cancer angiogenesis.
    Mol Cell Biol, 28(2): 772-83. [Abstract] [Full-text]
19. Parvin-beta inhibits breast cancer tumorigenicity and promotes CDK9-mediated peroxisome proliferator-activated receptor gamma 1 phosphorylation.
    Mol Cell Biol, 28(2): 687-704. [Abstract] [Full-text]
20. The role of dietary measurement error in investigating the hypothesized link between dietary fat intake and breast cancer--a story with twists and turns.
    Cancer Invest, 26(1): 68-73. [Abstract] [Full-text]
21. Antiproliferative and survival properties of PMA in MCF-7 breast cancer cell.
    Cancer Invest, 26(1): 13-21. [Abstract] [Full-text]
22. Epidermal growth factor (EGF) receptor targeted delivery of PEGylated adenovirus.
    Biochem Biophys Res Commun, 366(3): 769-74. [Abstract] [Full-text]
23. Variation of breast cancer risk among BRCA1/2 carriers.
    JAMA, 299(2): 194-201. [Abstract] [Full-text]
24. MOC-PSSM CME article: Breast reconstruction.
    Plast Reconstr Surg, 121(1): 1-12. [Abstract] [Full-text]
25. Tamoxifen-stimulated growth of breast cancer due to p21 loss.
    Proc Natl Acad Sci U S A, 105(1): 288-93. [Abstract] [Full-text]
26. Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer.
    Cancer Chemother Pharmacol, 61(4): 569-77. [Abstract] [Full-text]
27. Endogenous human microRNAs that suppress breast cancer metastasis.
    Nature, 451(7175): 147-52. [Abstract] [Full-text]
28. In vitro maturation of germinal vesicle oocytes recovered after premature luteinizing hormone surge: description of a novel approach to fertility preservation.
    Fertil Steril, 89(1): 228.e19-22. [Abstract] [Full-text]
29. Locus-specific and activity-independent gene repositioning during early tumorigenesis.
    J Cell Biol, 180(1): 39-50. [Abstract] [Full-text]
30. Hormono-biological therapy in metastatic breast cancer: preclinical evidence, clinical studies and future directions.
    Expert Opin Biol Ther, 8(2): 221-34. [Abstract] [Full-text]
31. Patterns of care analysis among women with ductal carcinoma in situ in North Carolina.
    Am J Surg, 195(2): 164-9. [Abstract] [Full-text]
32. Basal cell-like (triple-negative) breast cancer, a predictor of distant metastasis in African American women.
    Am J Surg, 195(2): 153-8. [Abstract] [Full-text]
33. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
    J Natl Cancer Inst, 100(2): 121-33. [Abstract] [Full-text]
34. Raman spectroscopy can differentiate malignant tumors from normal breast tissue and detect early neoplastic changes in a mouse model.
    Biopolymers, 89(3): 235-41. [Abstract] [Full-text]
35. The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer.
    Cancer Res, 68(2): 537-44. [Abstract] [Full-text]
36. CSN5 isopeptidase activity links COP9 signalosome activation to breast cancer progression.
    Cancer Res, 68(2): 506-15. [Abstract] [Full-text]
37. Cyclooxygenase-2 expression during immortalization and breast cancer progression.
    Cancer Res, 68(2): 467-75. [Abstract] [Full-text]
38. Nerve growth factor is a potential therapeutic target in breast cancer.
    Cancer Res, 68(2): 346-51. [Abstract] [Full-text]
39. Mechanism of leptin expression in breast cancer cells: role of hypoxia-inducible factor-1alpha.
    Oncogene, 27(4): 540-7. [Abstract] [Full-text]
40. Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer.
    J Clin Oncol, 26(3): 392-8. [Abstract] [Full-text]
41. Timing of menarche and first full-term birth in relation to breast cancer risk.
    Am J Epidemiol, 167(2): 230-9. [Abstract] [Full-text]
42. Telomere length inversely correlates with radiosensitivity in human carcinoma cells with the same tissue background.
    Biochem Biophys Res Commun, 367(1): 84-9. [Abstract] [Full-text]
43. Survival in breast cancer after nipple-sparing subcutaneous mastectomy and immediate reconstruction with implants: a prospective trial with 13 years median follow-up in 216 patients.
    Eur J Surg Oncol, 34(2): 143-8. [Abstract] [Full-text]
44. The value of MRI compared to mammography in the assessment of tumour extent in invasive lobular carcinoma of the breast.
    Eur J Surg Oncol, 34(2): 135-42. [Abstract] [Full-text]
45. A comparative study of risk factors and prognostic features between symptomatic and screen detected breast cancer.
    Eur J Surg Oncol, 34(2): 149-53. [Abstract] [Full-text]
46. Avoidance of axillary lymph node dissection in selected patients with node-positive breast cancer.
    Eur J Surg Oncol, 34(2): 129-34. [Abstract] [Full-text]
47. Lymphoepithelioma-like carcinoma of the breast: not Epstein-Barr virus-, but human papilloma virus-positive.
    Hum Pathol, 39(2): 298-301. [Abstract] [Full-text]
48. D2-40 expression by breast myoepithelium: potential pitfalls in distinguishing intralymphatic carcinoma from in situ carcinoma.
    Hum Pathol, 39(2): 175-83. [Abstract] [Full-text]
49. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
    Hum Pathol, 39(2): 167-74. [Abstract] [Full-text]
50. A novel gene STYK1/NOK is upregulated in estrogen receptor-alpha negative estrogen receptor-beta positive breast cancer cells following estrogen treatment.
    Mol Biol Rep, 35(1): 23-7. [Abstract] [Full-text]
51. Angiosarcoma of the breast.
    AJR Am J Roentgenol, 190(2): 533-8. [Abstract] [Full-text]
52. Lesion and patient characteristics associated with malignancy after a probably benign finding on community practice mammography.
    AJR Am J Roentgenol, 190(2): 511-5. [Abstract] [Full-text]
53. Correlation of whole-breast vascularity with ipsilateral breast cancers using contrast-enhanced MDCT.
    AJR Am J Roentgenol, 190(2): 496-504. [Abstract] [Full-text]
54. Role of sonography in the detection of contralateral metachronous breast cancer in an Asian population.
    AJR Am J Roentgenol, 190(2): 476-80. [Abstract] [Full-text]
55. PIK3CA cancer mutations display gender and tissue specificity patterns.
    Hum Mutat, 29(2): 284-8. [Abstract] [Full-text]
56. The contribution of dragon boat racing to women's health and breast cancer survivorship.
    Qual Health Res, 18(2): 222-33. [Abstract] [Full-text]
57. S-Allylcysteine reduces breast tumor cell adhesion and invasion.
    Biochem Biophys Res Commun, 367(2): 446-51. [Abstract] [Full-text]
58. Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer.
    Biochem Biophys Res Commun, 367(2): 235-41. [Abstract] [Full-text]
59. Oestrogen receptors alpha and beta show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer.
    J Clin Pathol, 61(2): 197-203. [Abstract] [Full-text]
60. MRI identifies otherwise occult disease in select patients with Paget disease of the nipple.
    J Am Coll Surg, 206(2): 316-21. [Abstract] [Full-text]
61. Predictors of breast asymmetry after breast-conserving operation for breast cancer.
    J Am Coll Surg, 206(2): 274-80. [Abstract] [Full-text]
62. Significance of sentinel lymph node micrometastases in human breast cancer.
    J Am Coll Surg, 206(2): 261-8. [Abstract] [Full-text]
63. Calcification in breast lesions: pathologists' perspective.
    J Clin Pathol, 61(2): 145-51. [Abstract] [Full-text]
64. Cyclin E confers a prognostic value in premenopausal breast cancer patients with tumours exhibiting an infiltrative growth pattern.
    J Clin Pathol, 61(2): 184-91. [Abstract] [Full-text]
65. Diagnostic accuracy of digital versus film mammography: exploratory analysis of selected population subgroups in DMIST.
    Radiology, 246(2): 376-83. [Abstract] [Full-text]
66. Basic physics and doubts about relationship between mammographically determined tissue density and breast cancer risk.
    Radiology, 246(2): 348-53. [Abstract] [Full-text]
67. Estrogen receptor-negative invasive breast cancer: imaging features of tumors with and without human epidermal growth factor receptor type 2 overexpression.
    Radiology, 246(2): 367-75. [Abstract] [Full-text]
68. The histone acetyltransferase hMOF is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastoma.
    Int J Cancer, 122(6): 1207-13. [Abstract] [Full-text]
69. Genetic predictors of long-term toxicities after radiation therapy for breast cancer.
    Int J Cancer, 122(6): 1333-9. [Abstract] [Full-text]
70. A stromal gene signature associated with inflammatory breast cancer.
    Int J Cancer, 122(6): 1324-32. [Abstract] [Full-text]
71. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.
    J Clin Oncol, 26(4): 592-8. [Abstract] [Full-text]
72. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer.
    J Clin Oncol, 26(4): 556-62. [Abstract] [Full-text]
73. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.
    J Clin Oncol, 26(4): 542-8. [Abstract] [Full-text]
74. Variable transcriptional activity of endogenous retroviruses in human breast cancer.
    J Virol, 82(4): 1808-18. [Abstract] [Full-text]
75. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer.
    J Clin Oncol, 26(4): 549-55. [Abstract] [Full-text]
76. The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation.
    Oncogene, 27(6): 865-76. [Abstract] [Full-text]
77. Empowering processes and outcomes of participation in online support groups for patients with breast cancer, arthritis, or fibromyalgia.
    Qual Health Res, 18(3): 405-17. [Abstract] [Full-text]

© 2004-2008 Breast Cancer Research Today. All Rights Reserved.